Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease
This article contains information on the experimental design and methods on how the safety and tolerability data concerning patients with moderate to very severe chronic obstructive pulmonary disease (COPD) were obtained. This is in addition to our original research article. [1] We have also provide...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-10-01
|
| Series: | Data in Brief |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352340919306316 |
| _version_ | 1818983857794318336 |
|---|---|
| author | James Donohue Edward Kerwin Sanjay Sethi Brett Haumann Srikanth Pendyala Lorna Dean Chris N. Barnes Edmund J. Moran Glenn Crater |
| author_facet | James Donohue Edward Kerwin Sanjay Sethi Brett Haumann Srikanth Pendyala Lorna Dean Chris N. Barnes Edmund J. Moran Glenn Crater |
| author_sort | James Donohue |
| collection | DOAJ |
| description | This article contains information on the experimental design and methods on how the safety and tolerability data concerning patients with moderate to very severe chronic obstructive pulmonary disease (COPD) were obtained. This is in addition to our original research article. [1] We have also provided information on the clinical laboratory tests that were conducted.Further interpretation and discussion of the data are demonstrated in the article “Revefenacin, a Once-daily, Lung-selective, Long-acting Muscarinic Antagonist for Nebulized Therapy: Safety and Tolerability Results of a 52-week Phase 3 Trial in Moderate to Very Severe Chronic Obstructive Pulmonary Disease.” [1] Keywords: Chronic obstructive pulmonary disease, COPD, Long-acting muscarinic antagonist, Nebulization, Revefenacin |
| first_indexed | 2024-12-20T18:09:47Z |
| format | Article |
| id | doaj.art-5f90e6e383d447dc9c566c6d8605769c |
| institution | Directory Open Access Journal |
| issn | 2352-3409 |
| language | English |
| last_indexed | 2024-12-20T18:09:47Z |
| publishDate | 2019-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Data in Brief |
| spelling | doaj.art-5f90e6e383d447dc9c566c6d8605769c2022-12-21T19:30:29ZengElsevierData in Brief2352-34092019-10-0126Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary diseaseJames Donohue0Edward Kerwin1Sanjay Sethi2Brett Haumann3Srikanth Pendyala4Lorna Dean5Chris N. Barnes6Edmund J. Moran7Glenn Crater8Pulmonary Medicine, UNC School of Medicine, Chapel Hill, NC, USAClinical Research Institute of Southern Oregon, PC, Medford, OR, USAUniversity at Buffalo, State University of New York, Buffalo, NY, USATheravance Biopharma US, Inc., South San Francisco, CA, USATheravance Biopharma US, Inc., South San Francisco, CA, USATheravance Biopharma US, Inc., South San Francisco, CA, USATheravance Biopharma US, Inc., South San Francisco, CA, USATheravance Biopharma US, Inc., South San Francisco, CA, USATheravance Biopharma US, Inc., South San Francisco, CA, USA; Corresponding author.This article contains information on the experimental design and methods on how the safety and tolerability data concerning patients with moderate to very severe chronic obstructive pulmonary disease (COPD) were obtained. This is in addition to our original research article. [1] We have also provided information on the clinical laboratory tests that were conducted.Further interpretation and discussion of the data are demonstrated in the article “Revefenacin, a Once-daily, Lung-selective, Long-acting Muscarinic Antagonist for Nebulized Therapy: Safety and Tolerability Results of a 52-week Phase 3 Trial in Moderate to Very Severe Chronic Obstructive Pulmonary Disease.” [1] Keywords: Chronic obstructive pulmonary disease, COPD, Long-acting muscarinic antagonist, Nebulization, Revefenacinhttp://www.sciencedirect.com/science/article/pii/S2352340919306316 |
| spellingShingle | James Donohue Edward Kerwin Sanjay Sethi Brett Haumann Srikanth Pendyala Lorna Dean Chris N. Barnes Edmund J. Moran Glenn Crater Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease Data in Brief |
| title | Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease |
| title_full | Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease |
| title_fullStr | Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease |
| title_full_unstemmed | Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease |
| title_short | Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease |
| title_sort | data on the safety and tolerability of revefenacin in patients with moderate to very severe chronic obstructive pulmonary disease |
| url | http://www.sciencedirect.com/science/article/pii/S2352340919306316 |
| work_keys_str_mv | AT jamesdonohue dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease AT edwardkerwin dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease AT sanjaysethi dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease AT bretthaumann dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease AT srikanthpendyala dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease AT lornadean dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease AT chrisnbarnes dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease AT edmundjmoran dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease AT glenncrater dataonthesafetyandtolerabilityofrevefenacininpatientswithmoderatetoveryseverechronicobstructivepulmonarydisease |